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+ $1M 10, 20, 40 or 80; or PBO. Primary efficacy endpoint was % reduction from baseline 
to endpoint in direct LDL-C for pooled EZE + SIM vs pooled SIM alone. 
Results: Table shows mean % change from baseline to endpoint. 
Treatment Direct LDL-C HDL-C TG 
PBO (n=70) -1.3 +0.9 +2.4 
EZE 10 mg (n=61) -18.1 +5.1 -6.3 
Pooled SIM (n=263) -36.1 +6.9 -16.6 
Pooled EZE + SIM (n=274) -49.9* +9.3" -24.1" 
*/~_0.03 for pooled EZE+SiM vs SIM 
EZE + SIM significantly improved LDL-C, HDL-C and TG compared to SIM alone 
(P<0.01). EZE provided an added 13.8% LDL-C reduction, 2.4% HDL-C increase and 
7.5% TG reduction compared to pooled SIM alone. EZE + SIM provided LDL-C reduc- 
tions of 44-57%, TG reductions of 20-28% and HDL-C increases of 8-11% depending on 
the dose. EZE 10 mg + SIM 10 mg and SIM 80 mg alone each provided 44% LDL-C 
reduction. EZE + SIM was well tolerated, with a safety profile similar to PBO. 
Conclusion; When co-administered with SIM, EZE provided significant incremental 
reductions in LDL-C and TG, as well as increases in HDL-C. The co-administration of 
EZE and SIM offers a highly efficacious new treatment approach to pts with hypercholes- 
terolemia. 
1084-91 Ezetimibe Co-Administered With Atorvastatin in 628 
Patients With Primary Hypercholesterolemia 
Christie Ballantvne. John Houri, Alberto Notarbartolo, Lorenzo Melani, Leslie Lipka, 
Alexandre LeBeaut, Ramachandran Suresh, Steven Sun, Enrico Vettri, for the Ezetimibe 
Study Group, Bay/or College of Medicine, Houston, Texas, Radiant Research, Stuart, 
Florida. 
Background: Efficacy and safety of ezetimibe (EZE) administered with atorvastatin 
(ATV) in pts with primary hypercholesterolemia were assessed in a Phase III, multicenter, 
randomized, double-blind, placebo-controlled study. 
Methods: After dietary stabilization on a NCEP Step I or stricter diet, a 2-12-wk screen- 
ing/washout period and a 4-wk, single-blind, PBO lead-in period, 626 pts with baseline 
LDL-C >_145 to _<250 mg/dl + TG _<350 mg/dl were randomized to 1 of the following 
administered daily for 12 consecutive wks: EZE 10 mg; ATV 10, 20, 40 or 80 mg; EZE 10 
mg + ATV 10, 20, 40 or 80 rag; or PBO. Primary efficacy endpoint was % reduction from 
baseline to endpoint in direct LDL-C for pooled EZE + ATV vs pooled ATV alone. 
Results: EZE + ATV was well tolerated, with a safety profile similar to ATV alone and to 
PBO. Table shows mean % chan~e from baseline to endpoint. 
Treatment Direct LDL-C HDL-C TG 
PBO (n=60) 5.9 3.7 4.4 
EZE 10 mg (n=65) -18.4 4.2 -3.4 
Pooled ATV (n=248) -42.4 4.3 -21.5 
Pooled EZE + ATV (n=255) -54.5* 7.3* -29.5* 
*,°<0.01 for pooled EZE+ATV vs ATV 
EZE + ATV significantly improved LDL-C, HDL-C and TG compared to ATV (P<0.01). 
EZE provided an added 12.1% LDL-C reduction, 3.0% HDL-C increase and an added 
8.0% TG reduction vs pooled ATV. EZE + ATV provided LDL-C reductions of 50-60%, TG 
reductions of 26-35% and HDL increases of 4.6-9.2% depending on the dose. LDL-C 
reduction with EZE 10 mg + ATV 10 mg (50%) and ATV 80 mg alone (51%) was similar. 
Conclusion: When co-administered with ATV, EZE provided significant incremental 
reductions in LDL-C and TG and increases in HDL-C. Co-administration of EZE and ATV 
offers a highly efficacious new treatment option for pts with hypercholesterolemia. 
1084-92 Ezetimibe Significantly Reduces Low-Density 
Lipoprotein Cholesterol in Homozygous Familial 
Hypercholesterolemia 
Claude Gagne, Daniel Gaudet. Eric Bruckert, Damien Ponsonnet, Leslie Lipka, 
Alexandre LeBeaut, Ramachandran Suresh, Paula Abreu, Enrico Veltri, for the Ezetimibe 
Study Group, Chul du Chuq, Ste-Foy, Quebec, Canada, Centre Hospitalier de la 
Sagamie - Clinique des Maladies Lipidiques, Chicoutimi, Quebec, Canada. 
Background: Current pharmacological agents for treatment of homozygous familial 
hypercholesterolemia (HoFH) have limited efficacy. We evaluated the efficacy, safety and 
tolerability of ezetimibe (EZE), a novel selective cholesterol absorption inhibitor, in HoFH 
pts already taking atorvastatin (A) or simvastatin (S). 
Methods: Fifty HoFH pts on diet and open-label 40 mg QD (A) or (S), with (n=26) or with- 
out (n=25) concomitant LDL apheresis, were randomized (double blind) to f of 3 daily 12- 
week treatments 1) A or S 60 rag, 2) EZE 10 mg+ A or S 40 rag, or 3) EZE 10 rag+ A or 
S 80 mg, The primary comparison was mean % change in LDL-C from baseline to end- 
point for the group receiving statins alone (Statin-80) vs the group receiving EZE + A or S 
at either dose (EZE+Statin-40/80). Mean % change in LDL-C for the group randomized 
to EZE + A or S 80 mg (EZE+Statin-80) was also compared to Statin-80. 
Results: The table shows least square mean LDL-C concentrations. 
Treatment LDL-C (mg/dl) % Change 
Baseline Endpoint (± SE) 
Statin 80 (n=17) 339 319 -6.7 ± 4.2 
EZE+Statin 40/80 (n=33) 313 247 -20.7 ± 3.2* 
EZE+Statin 80 (n=17) 273 196 -27.5 ± 3.5* 
*P < 0.01 vs. Statin-80 group 
Similar and significant LDL-C reductions were observed for the subset of pts who had a 
genotypic diagnosis of HoFH (n=32). No significant between-group differences were 
observed for HDL-C or TG. EZE was well tolerated as determined by safety laboratory, 
adverse event, and drug discontinuation assessments. 
Conclusion: EZE + A or S produced clinically important LDL-C lowering compared to 
best therapy with A and S in pts with HoFH. EZE provides a new, complementary phar- 
macological approach to this high-risk population. 
1084-93 Does Cholesterol and/or Fat Intake Affect Plasma Lipid 
Efficacy of Ezet imibe? 
Carlos Duiovne. Jolene Held, Leslie Lipka, Alexandre LeBeaut, Ramachandran Suresh, 
Enrico Veltd, for the Ezetimibe Study Group, Kansas Foundation for Clinical 
Pharmacology - Radiant Research, Kansas City, Kansas, Professional Nutrition 
Systems, Westwood, Kansas. 
Objective: To assess effect of degree of dietary saturated fat and cholesterol restriction 
on efficacy of ezetimibe (EZE), a new selective cholesterol absorption inhibitor, in 1719 
patients with primary hyperchelesterolemia. 
Methods: After 6-8 weeks instruction of NCEP Step I or stricter diet during the single- 
blind PBO lead-in, patients with plasma LDL-C 130-250 mg/dt and TG <_350 mg/dl were 
randomized 3:1 to EZE 10 mg/d or PBO for 12 weeks in 2 identically designed Phase III, 
double-blind studies. Data from these 2 studies were pooled for analysis. Primary end- 
point was % reduction of direct LDL-C from baseline to endpoint. Diet compliance was 
assessed every 2-6 weeks at a centralized center by computer analysis of 3-day food- 
intake records. A RISCC (Ratio of Ingeste d Saturated Fat and Cholesterol over Calories) 
score was used to quantitate all fat-related diet components and to compare diets 
between treatments. RISCC=(1.01[saturated fat in g] + 0.05[cholesterol in mg]) + (total 
Kcal/1000). 
Results: Of 1,719 patients (831 men, 888 women; ages 18-86 y), 1286 were randomized 
to EZE and 431 to PBO. Baseline characteristics were comparable between groups. The 
% change (mean ± SEM) in plasma lipid from baseline to endpoint was used to compare 
st EZE and PBO patients in the 1 quartile (lowest) and 4 th quartile (highest) of RISCC val- 
ues (-<13, and ->20) and dietary cholesterol (<_124, and ->250 rag) at baseline. For EZE 
patients, % LDL-C reduction was -19 + 0.6 and -19 _+ 0.6 for patients in the 4 th quartile of 
RISCC (n=353) or cholesterol (n=319), respectively, vs -16 ¢ 0.6 and -17 _+ 0.6 for 
patients in the 1 st quartile of RISCC (n=335) or cholesterol (n=300), respectively. For 
+ th PBO, % LDL-C reduction was -1+ 1 and -0.1 _ 1 for patients in the 4 quartile of RISCC 
(n=109) or cholesterol (n=95), respectively, vs -0.5 _+ 1 and 0.1 _+ 1 for patients in the 1 st 
quartile of RISCC (n=114) or cholesterol (n=115), respectively. The % change LDL-C in 
the 1st and 4th quartites was similar for EZE vs PBO.Conclusions: LDL-C Iowedeg 
attributable to EZE for the lowest and highest quartiles of cholesterol or fat intake did not 
differ significantly. 
1084-94 Atazanavir Plus Saquinavir Once Daily: Favorable 
Effects on Lipid Profiles in Patients Failing Prior 
Protease Inhibitor Therapy (Trial AI424-009) 
David W. Haas, Carlos Zala, Shannon Schrader, Alexandra Thiry, Rachel McGovern, 
Steven Schnittman. Vanderbilt University Medical Center, Nashville, Tennessee. 
Background: Currently approved RIV-1 protease inhibitors (PIs) may increase risk for 
CV events by altering lipid metabolism. Atazanavir (BMS-232632) is a once-daily PI that 
rapidly and durably suppresses HIV RNA and increases CD4. Atazanavir does not 
increase total cholesterol (TC), low-density lipoprotein cholesterol (LDL), or trigtycaride 
(TG) levels in antiretroviral-nai've subjects compared with prompt, marked, and sustained 
elevations with current PIs. Atazanavir and saquinavir have complementary resistance 
profiles and favorable PK interactions allowing for once-daily dosing of the combination. 
This protocol evaluated the safety, tolerability, and efficacy of dual PI therapy with ataza- 
navir (400 or 606 mg qd)/saquinavir (1,200 mg qd) or ritonavir (400 mg bid)/saquinavir 
(400 mg bid) + 2 NRTIs after virologic failure on a PI regimen. 
Methods: Randomized, active-controlled, blinded study in 85 adults with HIV RNA 
1,000-100,000 c/mL and CD4 -> 100 cells/mm 3, 
Results: Wk 24, Observed Data 
Atazanavir/saquinavir once daily Ritonavir/saquinavir 
twice daily 
400 mo (n=~4) 600 me (n=28~ 400 mo fn=231 
Median baseline, mg/dL (mean % change from baseline, n) 
TG 223 (-23, 15) 177 (-21, 13) 191 (90, 8) 
TC 181 (-1,27) 199 (-9, 20) 202 (10, 13) 
Mean change from baseline (SE, n) 
HIV RNA (log10 c/mL) -1.26 (0.20, 29) -1.17 (0.20, 22) -1.50 (0.31, 13) 
CD4 (calls/mm 3) 55 (17, 29) 67 (18, 22) 98 (25, 13) 
Updated results to wk 48 will be presented. Conclusion: In subjects failing a prior PI reg- 
imen, atazanavidsaquinavir lowered TC, LDL, and TG levels from baseline, whereas 
ritonavir/saquinavir produced substantial increases. Atazanavir/saquinavir was safe and 
well tolerated and showed significant antiviral effect at wk 24. The ability to improve 
serum lipid profiles in PI-experienced subjects suggests that atazanavir educes risk fac- 
tors for CV events in this population. 
